Tesamorelin Side Effects and Safety
Reported Tesamorelin side effects, contraindications, and safety signals.
Safety & Contraindications
Tesamorelin is a research compound and is not FDA-approved for general use. It should be avoided by anyone with active malignancy, pregnancy, and pituitary disorder. Most reported effects are mild and dose-dependent, so start at the low end of the dosing range and titrate up slowly rather than chasing a maximal dose. Injection-site redness, itching, or a temporary lump are the most common local reactions; rotate sites and use clean technique to keep them minimal.
What to Monitor
Track waist circumference, IGF-1, HbA1c, fasting glucose, and triglycerides while you're running Tesamorelin so you can catch any drift early and adjust before it becomes a problem. Add these to your REGEN biomarker dashboard and re-check on your normal cadence.
Contraindications
- active malignancy
- pregnancy
- pituitary disorder
References
- Effects of tesamorelin on visceral fat in HIV-associated lipodystrophy
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370.
- Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.
- FDA prescribing information
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291-4304.
- Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.